Moderna (MRNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$145.55-2.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Achieve up to 10% revenue growth in 2026: FY26 revenue guidance $1.1B vs FY25 $1.9B implies -42% YoY vs 10% target.
Moderna aims for up to 10% revenue growth in 2026. It plans to keep a strong cash position near $7.5 billion. The company is expanding its mRNA platform and launching new vaccines. These moves could help it recover from recent losses.
Moderna is losing money and cut its guidance recently. Operating costs rose sharply to $1.8 billion in Q1 2026. FDA scrutiny may delay key product approvals. These issues could hurt growth and cash flow.
The price is about 37% above our fair value near $58. Analysts expect 9% revenue growth. We see risks from losses and cost pressures not fully priced in.
Breaks if: Cash and investments fall below 7.0 billion USD
Breaks if: Operating expenses rise above 1.8 billion USD per quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on the biotechnology sector. The current thesis state indicates a watchful approach due to recent underperformance compared to peers and a mixed outlook on management execution.
The market appears to price in a premium compared to peers, reflecting expectations that may not be justified given the company's current losses and weak financial results. There is a notable expectations gap, suggesting that investors may be overly optimistic about future performance.
Management has set targets for revenue growth, but recent financial performance has been weak. The company is maintaining a strong cash position, although cash reserves are decreasing, which could impact future operations.
The thesis hinges on several factors, including management's ability to meet revenue growth targets and control operating expenses. Additionally, the performance of sector peers could influence MRNA's trajectory, especially if they continue to show strength in earnings.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The FDA approved Moderna's updated COVID-19 vaccines, enhancing growth prospects. However, the company faces challenges as it targets up to 10% revenue growth in 2026. This guidance appears at risk due to significant revenue declines.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Moderna is focused on reducing GAAP operating expenses in 2026.
Breaks if: Operating margin falls below 4.2 billion USD in FY26
Moderna is focused on reducing GAAP operating expenses in 2026.
Breaks if: YoY revenue growth falls below ~9% in FY26
In the next 1 to 3 years, MRNA's outlook remains uncertain, influenced by both internal management execution and external market conditions. Not investment advice.